Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: Avalon Pharmaceuticals (AVRX)

No earlier versions found for this Subject.

Return to Avalon Pharmaceuticals (AVRX)

Avalon Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of small molecule therapeutics for the treatment of cancer. Their pipeline of drug candidates includes their lead candidate, AVN944. AVN944 is an oral delivery, small molecule drug candidate that was discovered by Vertex Pharmaceuticals Incorporated and that they licensed from Vertex in February 2005.

IPO date is 9/26/2005

Pricing $10 to $12

Shares 2,750,000

Lead Manager: WR Hambrecht + Co.

Is this company worth it?